Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches
March 23, 2026, 3:33 pm
Everest Medicines is reshaping its market footprint. The biopharmaceutical giant secured rights to CARDAMYST™ (etripamil) nasal spray for Greater China. This innovative therapy targets paroxysmal supraventricular tachycardia (PSVT), offering at-home treatment. Simultaneously, Everest plans to acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., expanding its reach across the Asia-Pacific region. These moves bolster Everest's cardiovascular and chronic disease portfolios. They solidify its "2030 Strategy," aiming for leadership in global biopharma. Everest leverages strong clinical data and a robust commercial platform. The company prioritizes unmet medical needs, delivering advanced patient care.
Everest Medicines is rapidly expanding its influence. The biopharmaceutical firm recently announced two strategic moves. These initiatives aim to solidify its position in Asia's healthcare landscape. Everest is building a powerhouse. It focuses on innovative therapeutics and broad market access.
One significant development involves CARDAMYST™ (etripamil) nasal spray. Everest Medicines secured exclusive rights for Greater China. This deal with Corxel Pharmaceuticals Hong Kong Limited is a game-changer. It grants Everest the power to develop, manufacture, and commercialize this critical drug. The agreement involved an initial US$30 million payment. Additional development milestones could reach US$20 million.
CARDAMYST™ represents a new era in cardiac care. It is a rapid-acting calcium channel blocker. Patients administer it as a convenient nasal spray. This allows for at-home use. The therapy offers quick action and good tolerability. The U.S. Food and Drug Administration (FDA) approved CARDAMYST™ in December 2025. It became the first self-administered nasal spray in over 30 years. It treats paroxysmal supraventricular tachycardia (PSVT) in adults. PSVT involves sudden episodes of rapid heart rate. Current options often require emergency room visits. CARDAMYST™ shifts treatment control to the patient.
China's healthcare market presents a vast opportunity. The New Drug Application (NDA) for etripamil nasal spray received NMPA acceptance in January 2025. Approval is anticipated by the third quarter of 2026. PSVT affects 3 to 6 million Chinese patients. There are currently no approved self-administered, fast-acting, non-injectable treatments. This creates a substantial unmet medical need. Everest aims to fill this void.
Beyond PSVT, etripamil shows promise for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials yielded encouraging results. Phase III trials are in planning. This could expand the drug's therapeutic impact. AFib-RVR affects nearly 20 million patients in China. The condition carries risks like stroke and heart failure. Everest's acquisition strategically targets these widespread cardiovascular conditions.
In a separate but equally impactful move, Everest Medicines announced a letter of intent. The company plans a possible acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. This Singapore-based entity specializes in commercializing prescription drugs. Its focus lies in chronic diseases and acute care, specifically cardiovascular and metabolic segments.
Hasten Biopharmaceuticals (SG) holds rights for 14 branded chronic disease products. These cover multiple countries across the Asia-Pacific region. This potential acquisition would significantly expand Everest's footprint. It supplements Everest's existing pipeline. It also boosts its strategic presence in the vital Asia-Pacific market. A refundable deposit of RMB200 million commenced the process. This deposit will form part of the acquisition consideration. Everest will conduct due diligence. A six-month exclusivity period is in place.
The Southeast Asia region alone boasts a population of approximately 600 million. It suffers from significant unmet medical needs. The market potential for chronic disease management is enormous. Everest's current pipeline already targets CKM (cardiovascular, kidney, and metabolic) diseases. This creates strong synergies with Hasten's portfolio. Everest seeks to accelerate its product commercialization in these key Asian markets. This includes products like NEFECON®, VELSIPITY®, and XERAVA®. These drugs are progressing through regulatory approvals and reimbursement inclusions.
Everest's "2030 Strategy" underpins these aggressive expansion efforts. The company employs a "dual-engine approach." This combines strategic business development partnerships with internal R&D. These recent transactions strengthen Everest's cardiovascular franchise. They reinforce its disciplined approach to therapeutic verticals. The company aims for meaningful lifecycle expansion potential.
Robust clinical data supports the CARDAMYST™ acquisition. The global Phase 3 RAPID study published in The Lancet confirmed efficacy. It showed 64% of etripamil recipients converted to sinus rhythm within 30 minutes. This compared to 31% on placebo. The median conversion time was 17 minutes for etripamil. China's Phase 3 JX02002 study mirrored these positive results. Safety profiles across both trials were favorable. Adverse events were generally mild and transient. No serious adverse events were reported within 24 hours. The AFib-RVR Phase 2 ReVeRA study also demonstrated significant ventricular rate reduction.
Everest has already established a strong commercialization platform. Its success with NEFECON® in China demonstrates this capability. The Hasten acquisition builds on this foundation. It allows Everest to leverage its expertise across a broader geographic area. The goal is to drive overseas sales revenue. These steps are crucial towards Everest's vision. The company seeks to evolve into a leading global biopharmaceutical company.
These strategic maneuvers position Everest Medicines for substantial growth. They highlight a commitment to patient-centric innovation. By acquiring key product rights and expanding commercially, Everest aims to address critical unmet medical needs. It delivers innovative therapies to more patients. The company builds sustainable long-term value. Everest is not just growing; it is redefining its future.
Everest Medicines is rapidly expanding its influence. The biopharmaceutical firm recently announced two strategic moves. These initiatives aim to solidify its position in Asia's healthcare landscape. Everest is building a powerhouse. It focuses on innovative therapeutics and broad market access.
One significant development involves CARDAMYST™ (etripamil) nasal spray. Everest Medicines secured exclusive rights for Greater China. This deal with Corxel Pharmaceuticals Hong Kong Limited is a game-changer. It grants Everest the power to develop, manufacture, and commercialize this critical drug. The agreement involved an initial US$30 million payment. Additional development milestones could reach US$20 million.
CARDAMYST™ represents a new era in cardiac care. It is a rapid-acting calcium channel blocker. Patients administer it as a convenient nasal spray. This allows for at-home use. The therapy offers quick action and good tolerability. The U.S. Food and Drug Administration (FDA) approved CARDAMYST™ in December 2025. It became the first self-administered nasal spray in over 30 years. It treats paroxysmal supraventricular tachycardia (PSVT) in adults. PSVT involves sudden episodes of rapid heart rate. Current options often require emergency room visits. CARDAMYST™ shifts treatment control to the patient.
China's healthcare market presents a vast opportunity. The New Drug Application (NDA) for etripamil nasal spray received NMPA acceptance in January 2025. Approval is anticipated by the third quarter of 2026. PSVT affects 3 to 6 million Chinese patients. There are currently no approved self-administered, fast-acting, non-injectable treatments. This creates a substantial unmet medical need. Everest aims to fill this void.
Beyond PSVT, etripamil shows promise for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials yielded encouraging results. Phase III trials are in planning. This could expand the drug's therapeutic impact. AFib-RVR affects nearly 20 million patients in China. The condition carries risks like stroke and heart failure. Everest's acquisition strategically targets these widespread cardiovascular conditions.
In a separate but equally impactful move, Everest Medicines announced a letter of intent. The company plans a possible acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. This Singapore-based entity specializes in commercializing prescription drugs. Its focus lies in chronic diseases and acute care, specifically cardiovascular and metabolic segments.
Hasten Biopharmaceuticals (SG) holds rights for 14 branded chronic disease products. These cover multiple countries across the Asia-Pacific region. This potential acquisition would significantly expand Everest's footprint. It supplements Everest's existing pipeline. It also boosts its strategic presence in the vital Asia-Pacific market. A refundable deposit of RMB200 million commenced the process. This deposit will form part of the acquisition consideration. Everest will conduct due diligence. A six-month exclusivity period is in place.
The Southeast Asia region alone boasts a population of approximately 600 million. It suffers from significant unmet medical needs. The market potential for chronic disease management is enormous. Everest's current pipeline already targets CKM (cardiovascular, kidney, and metabolic) diseases. This creates strong synergies with Hasten's portfolio. Everest seeks to accelerate its product commercialization in these key Asian markets. This includes products like NEFECON®, VELSIPITY®, and XERAVA®. These drugs are progressing through regulatory approvals and reimbursement inclusions.
Everest's "2030 Strategy" underpins these aggressive expansion efforts. The company employs a "dual-engine approach." This combines strategic business development partnerships with internal R&D. These recent transactions strengthen Everest's cardiovascular franchise. They reinforce its disciplined approach to therapeutic verticals. The company aims for meaningful lifecycle expansion potential.
Robust clinical data supports the CARDAMYST™ acquisition. The global Phase 3 RAPID study published in The Lancet confirmed efficacy. It showed 64% of etripamil recipients converted to sinus rhythm within 30 minutes. This compared to 31% on placebo. The median conversion time was 17 minutes for etripamil. China's Phase 3 JX02002 study mirrored these positive results. Safety profiles across both trials were favorable. Adverse events were generally mild and transient. No serious adverse events were reported within 24 hours. The AFib-RVR Phase 2 ReVeRA study also demonstrated significant ventricular rate reduction.
Everest has already established a strong commercialization platform. Its success with NEFECON® in China demonstrates this capability. The Hasten acquisition builds on this foundation. It allows Everest to leverage its expertise across a broader geographic area. The goal is to drive overseas sales revenue. These steps are crucial towards Everest's vision. The company seeks to evolve into a leading global biopharmaceutical company.
These strategic maneuvers position Everest Medicines for substantial growth. They highlight a commitment to patient-centric innovation. By acquiring key product rights and expanding commercially, Everest aims to address critical unmet medical needs. It delivers innovative therapies to more patients. The company builds sustainable long-term value. Everest is not just growing; it is redefining its future.